{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anti-anxiety+Agents",
    "query": {
      "condition": "Anti-anxiety Agents"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anti-anxiety+Agents&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-27T12:54:38.694Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03297944",
      "title": "Sedative-Anxiolytic Effects on Simulated Driving Performance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psychomotor Impairment"
      ],
      "interventions": [
        {
          "name": "Alprazolam 2mg (2ALP/PLC)",
          "type": "DRUG"
        },
        {
          "name": "Alprazolam 1mg (1ALP/PLC)",
          "type": "DRUG"
        },
        {
          "name": "Alprazolam 0.5mg (0.5ALP/PLC)",
          "type": "DRUG"
        },
        {
          "name": "Zolpidem 10mg (ZOL/PLC)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (PLC/PLC)",
          "type": "DRUG"
        },
        {
          "name": "Alprazolam 1mg (PLC/ALC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marion Coe",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 15,
      "start_date": "2017-09-15",
      "completion_date": "2018-10-25",
      "has_results": true,
      "last_update_posted_date": "2020-01-29",
      "last_synced_at": "2026-06-27T12:54:38.694Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03297944"
    },
    {
      "nct_id": "NCT06615557",
      "title": "Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Social Anxiety Disorder (SAD)"
      ],
      "interventions": [
        {
          "name": "Fasedienol Nasal Spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo Nasal Spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VistaGen Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 238,
      "start_date": "2024-09-16",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-27T12:54:38.694Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06615557"
    },
    {
      "nct_id": "NCT00706836",
      "title": "PharmacofMRI of Anxiolytic Medications (Pregabalin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anxiety Disorders"
      ],
      "interventions": [
        {
          "name": "Pregabalin 50mg",
          "type": "DRUG"
        },
        {
          "name": "Pregabalin 200 MG",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 16,
      "start_date": "2008-06",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2019-04-09",
      "last_synced_at": "2026-06-27T12:54:38.694Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00706836"
    },
    {
      "nct_id": "NCT03017508",
      "title": "Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Social Anxiety Disorder",
        "Performance Anxiety"
      ],
      "interventions": [
        {
          "name": "BHV-0223",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "2017-01",
      "completion_date": "2021-01-29",
      "has_results": true,
      "last_update_posted_date": "2021-05-20",
      "last_synced_at": "2026-06-27T12:54:38.694Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03017508"
    },
    {
      "nct_id": "NCT06809179",
      "title": "A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Social Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Fasedienol Nasal Spray - Placebo Nasal Spray",
          "type": "DRUG"
        },
        {
          "name": "Fasedienol Nasal Spray - Fasedienol Nasal Spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo Nasal Spray - Placebo Nasal Spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VistaGen Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2025-01-09",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-06-27T12:54:38.694Z",
      "location_count": 9,
      "location_summary": "Sherman Oaks, California • Walnut Creek, California • Largo, Florida + 6 more",
      "locations": [
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Toms River",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06809179"
    },
    {
      "nct_id": "NCT05610969",
      "title": "Music vs Midazolam During Preop Nerve Block Placement - Part 2 Study On Anxiolytic Options Before Peripheral Nerve Blocks",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Peripheral Nerve Block",
        "Anxiety",
        "Preoperative Anxiety"
      ],
      "interventions": [
        {
          "name": "Music",
          "type": "OTHER"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2021-09-01",
      "completion_date": "2023-05-08",
      "has_results": true,
      "last_update_posted_date": "2025-05-14",
      "last_synced_at": "2026-06-27T12:54:38.694Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05610969"
    },
    {
      "nct_id": "NCT04565145",
      "title": "Biomarker Changes and Anxiolytic Effects-Phase 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Kava Dietary Supplement",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 39,
      "start_date": "2021-04-05",
      "completion_date": "2023-07-01",
      "has_results": true,
      "last_update_posted_date": "2024-08-13",
      "last_synced_at": "2026-06-27T12:54:38.694Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04565145"
    },
    {
      "nct_id": "NCT06182631",
      "title": "Clinical Trial Testing Buzzy Bee vs Vapocoolant During IV Placement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Intravenous Administration"
      ],
      "interventions": [
        {
          "name": "Buzzy Bee",
          "type": "DEVICE"
        },
        {
          "name": "Vapocoolent",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Years to 18 Years"
      },
      "enrollment_count": 172,
      "start_date": "2019-07-15",
      "completion_date": "2021-01-15",
      "has_results": true,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-06-27T12:54:38.694Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06182631"
    },
    {
      "nct_id": "NCT00703885",
      "title": "PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anxiety Disorders"
      ],
      "interventions": [
        {
          "name": "0.25 mg alprazolam",
          "type": "DRUG"
        },
        {
          "name": "1.0 mg alprazolam",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 16,
      "start_date": "2008-01",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2014-12-22",
      "last_synced_at": "2026-06-27T12:54:38.694Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00703885"
    },
    {
      "nct_id": "NCT01431326",
      "title": "Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adenovirus",
        "Anesthesia",
        "Anxiety",
        "Anxiolysis",
        "Autism",
        "Autistic Disorder",
        "Bacterial Meningitis",
        "Bacterial Septicemia",
        "Benzodiazepine",
        "Bipolar Disorder",
        "Bone and Joint Infections",
        "Central Nervous System Infections",
        "Convulsions",
        "Cytomegalovirus Retinitis",
        "Early-onset Schizophrenia Spectrum Disorders",
        "Epilepsy",
        "General Anesthesia",
        "Gynecologic Infections",
        "Herpes Simplex Virus",
        "Infantile Hemangioma",
        "Infection",
        "Inflammation",
        "Inflammatory Conditions",
        "Intra-abdominal Infections",
        "Lower Respiratory Tract Infections",
        "Migraines",
        "Pain",
        "Pneumonia",
        "Schizophrenia",
        "Sedation",
        "Seizures",
        "Skeletal Muscle Spasms",
        "Skin and Skin-structure Infections",
        "Treatment-resistant Schizophrenia",
        "Urinary Tract Infections",
        "Withdrawal",
        "Sepsis",
        "Gram-negative Infection",
        "Bradycardia",
        "Cardiac Arrest",
        "Cardiac Arrhythmia",
        "Staphylococcal Infections",
        "Nosocomial Pneumonia",
        "Neuromuscular Blockade",
        "Methicillin Resistant Staphylococcus Aureus",
        "Endocarditis",
        "Neutropenia",
        "Headache",
        "Fibrinolytic Bleeding",
        "Pulmonary Arterial Hypertension",
        "CMV Retinitis",
        "Hypertension",
        "Chronic Kidney Diseases",
        "Hyperaldosteronism",
        "Hypokalemia",
        "Heart Failure",
        "Hemophilia",
        "Heavy Menstrual Bleeding",
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel Benjamin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 3520,
      "start_date": "2011-11",
      "completion_date": "2019-11",
      "has_results": false,
      "last_update_posted_date": "2023-09-06",
      "last_synced_at": "2026-06-27T12:54:38.694Z",
      "location_count": 43,
      "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01431326"
    }
  ]
}